DMK Pharmaceuticals Corporation
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergen… Read more
Market Cap & Net Worth: DMK Pharmaceuticals Corporation (DMKPQ)
DMK Pharmaceuticals Corporation (PINK:DMKPQ) has a market capitalization of $0.99 ($0.99) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #48136 globally and #14812 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying DMK Pharmaceuticals Corporation's stock price $0.00 by its total outstanding shares 9889 (9.89K).
DMK Pharmaceuticals Corporation Market Cap History: 2015 to 2025
DMK Pharmaceuticals Corporation's market capitalization history from 2015 to 2025. Data shows change from $3.74 Million to $0.99 (-79.11% CAGR).
DMK Pharmaceuticals Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how DMK Pharmaceuticals Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
DMK Pharmaceuticals Corporation's market cap is 0.02 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.18 Million | $6.47 Million | -$19.44 Million | 0.34x | N/A |
| 2017 | $3.05 Million | $13.07 Million | -$25.54 Million | 0.23x | N/A |
| 2018 | $1.56 Million | $15.09 Million | -$39.01 Million | 0.10x | N/A |
| 2019 | $484.56K | $22.11 Million | -$27.51 Million | 0.02x | N/A |
| 2020 | $339.19K | $2.78 Million | -$49.39 Million | 0.12x | N/A |
| 2021 | $422.26K | $2.21 Million | -$45.83 Million | 0.19x | N/A |
| 2022 | $117.68K | $4.76 Million | -$26.48 Million | 0.02x | N/A |
Competitor Companies of DMKPQ by Market Capitalization
Companies near DMK Pharmaceuticals Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to DMK Pharmaceuticals Corporation by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
DMK Pharmaceuticals Corporation Historical Marketcap From 2015 to 2025
Between 2015 and today, DMK Pharmaceuticals Corporation's market cap moved from $3.74 Million to $ 0.99, with a yearly change of -79.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $0.99 | -99.99% |
| 2023 | $6.92K | -94.12% |
| 2022 | $117.68K | -72.13% |
| 2021 | $422.26K | +24.49% |
| 2020 | $339.19K | -30.00% |
| 2019 | $484.56K | -68.89% |
| 2018 | $1.56 Million | -48.86% |
| 2017 | $3.05 Million | +39.68% |
| 2016 | $2.18 Million | -41.67% |
| 2015 | $3.74 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of DMK Pharmaceuticals Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $0.99 USD |
| MoneyControl | $0.99 USD |
| MarketWatch | $0.99 USD |
| marketcap.company | $0.99 USD |
| Reuters | $0.99 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.